

Partnering within our communities to provide solutions for better health

P.O. Box 5119, Helena, MT 59604 Phone 406.443.6002 . Toll-Free 1.800.395.7961 Fax 406.513.1928 . Toll-Free 1.800.294.1350

Montana Healthcare Programs Prior Authorization Request Form for Use of Promacta (eltrombopag)

Member Name:	DOB:	Date:
Member ID:	Prescriber Phone/Fax:	
Prescriber Name:	Prescriber Specialty:	
Requested Dose/Directions:		
Diago complete below information for applicable situati	ion Initiation	on Continuation of thousans and attach
Please complete below information for applicable situati supporting documentation:	on, <u>Initiation</u>	or <u>Continuation</u> of therapy and attach
INITIATION OF THERAPY		
 Prescriber is a hematologist and has diagnosed the condition ☐ Yes ☐ No 		
2. Baseline platelet count (must be $< 30 \times 10^9/L$) Date:		
 Lab results and chart notes from the last 12 months are attached (required). Prescriber attests that baseline clinical hematology and liver function tests have been performed and will be measured. 		
at least monthly throughout course of treatment \square Yes \square No		
5. Diagnosis/age requirements:		
☐ Chronic Immune Thrombocytopenia (ITP)		
 Member age is ≥1 year □ Yes □ No 		
Member has trialed at least <u>one</u> of the following (circle):		
Corticosteroids OR immunoglobulins OR rituximab OR splenectomy New Assistation and Asia for the Management of the Control of the Contro		
 ■ Member is at increased risk for bleeding due to clinical condition □ Yes □ No □ First-line treatment of Severe Aplastic Anemia 		
■ Member age is ≥2 years: □ Yes □ No		
 Standard first-line immunosupressive therapy (i.e., h-ATG and cyclosporine) is being used 		
concurrently: ☐ Yes ☐ No		
☐ Refractory Severe Aplastic Anemia (monotherapy)		
 Member age is ≥ 18 years □ Yes □ No Member had an insufficient response to at least one prior immunosuppressive therapy □ Yes □ No. 		
 Member had an insufficient response to at least one prior immunosuppressive therapy □ Yes □ No 		
LIMITATIONS: ITP, max daily 75mg. Severe Aplastic Anemia, max daily 150 mg. Initial authorization for 6 months.		
CONTINUATION OF THERAPY		
1. Diagnosis for treatment:		
	,	
 Provide current platelet count: AND/OR decomposition that members	has avnariance	$be > 50 \times 10^{9}/L$) Date:
[attach platelet lab results and chart n		
☐ Refractory Severe Aplastic Anemia Monot		ioning 1
		last 6 months and chart notes documenting
2. Clinical hematology and liver function tests will continue to be monitored <u>at least monthly</u> : ☐ Yes ☐ No		
Reauthorization will be issued for 6 months.		